Lipocine Inc.

SALT LAKE CITY, X1 · Founded 2011 · Biotech · Public

Proprietary drug formulation and delivery technology platform for oral pharmaceuticals

Claim this profile

Follows are private to you and power your alerts

Updated · lipocine.com

Sector
Biotech
Headquarters
SALT LAKE CITY, X1
Founded
2011
Latest Form D
Aug 2013
Total capital
$38M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$38M
2 Form D · last Aug 2013
159 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
31
9 pending · first 2022
Rank in peer group#25 of 1449

Capital timeline

2013FEDERAL ↑EQUITY ↓Cumulative $38M1st Form D$38M
2013FEDERAL ↑EQUITY ↓Cumulative $38M1st Form D$38M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$38M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#25 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Mahesh V. PatelResearcherExecutive Officer, DirectorLinked by 6 patents
  • Gerald K. SimmonsExecutive OfficerNamed in SEC Form D filings
  • Gordhan K. PatelDirectorNamed in SEC Form D filings
  • John W. HiguchiDirectorNamed in SEC Form D filings
  • Robert K. MerrellExecutive OfficerNamed in SEC Form D filings
  • Srinivasan K. VenkateshwaranExecutive OfficerNamed in SEC Form D filings
Show all 7 people
  • William I. HiguchiDirectorNamed in SEC Form D filings

What it has protected

USPTO · 31 granted of 40
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .